

R&D Pipeline¹

| Key Clinical Programs | Phase 1 | Phase 2 | Phase 3 | Approval/Launch | Notes |
|--|---------|---------|---------|-----------------|--|
| DERMATOLOGY | | | | | |
| CABTREGO[®] First triple combination product for the treatment of acne vulgaris | | | | | First and only FDA-approved fixed-dose, triple-combination topical treatment for acne successfully launched in the U.S. in 1Q 2024 Launched in Canada in October 2024 |
| SALIX | | | | | |
| RED-C Prevention and delay of first episode of hepatic encephalopathy | | | | | Both RED-C global Phase 3 trials currently in treatment phase On track for top-line Phase 3 results by early 2026 |
| Amiselimod (S1P modulator) Treatment for mild to moderate ulcerative colitis | | | | | Submitted draft protocols for Phase 3 trial addressing moderate- to severe- Ulcerative Colitis patients Met with all planned major regulatory bodies (FDA, EMA (EU), and PMDA (Japan) by year-end 2024 All regulatory feedback under review |
| SOLTA MEDICAL | | | | | |
| Thermage[®] FLX Radio-frequency technology to help tighten and improve the smoothness and texture of skin's surface | | | | | Received National Medical Products Administration (NMPA) approval in China in January 2024, followed by a successful launch Submitted for approval in Canada during 4Q 2024 |
| Clear + Brilliant[®] Touch Fractionated laser device for skin rejuvenation | | | | | Ex-U.S., approvals by the end of 2024 have been received for Australia, New Zealand, Philippines, Thailand, Taiwan, Malaysia and Singapore Submitted for approval in Canada during 4Q 2024; Awaiting European regulatory response to submission |
| Next Generation Fraxel[®] Fractionated laser device for skin resurfacing | | | | | Received FDA clearance in August 2024 U.S. commercial launch expected in 2025 |

1. Progress timelines are for illustrative purposes only; See Slide 2 for further information on forward-looking statements.